Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Biorphen, Vazculep, Lusonal
Synonyms :
phenylephrine, Phenylephrinum, Fenilefrina
Class :
Alpha1 Agonists, Vasopressors
Dosage Forms & StrengthsÂ
Injectable IV solutions in concentrated formÂ
10mg/mL (Biorphen, Vazculep)Â
Need further dilutionÂ
Injectable IV solution as ready-to-useÂ
0.1 mg/mL (Biorphen)Â
Should not dilute furtherÂ
Indicated for Severe Hypotension or Shock
Intravenous bolus: 40-100 mcg every 1-2 minutes as needed. Should not exceed the total dose 200 mcg
Adjust the dosage depending on the blood pressure levels
Continuous intravenous infusion: If the blood pressure levels are less than the target levels, start a continuous intravenous infusion of 10-35 mcg/min. Should not exceed 200 mcg/min
Note:
Renal impairment
End-stage renal disease: Data of dose-response indicate enhanced responsiveness to the phenylephrine
Mild-moderate: Start at low dose of the recommended dose and thereafter adjust the dose depending on blood pressure levels
Hepatic impairment
Moderate-severe: Data of dose-response indicate diminished responsiveness to the phenylephrine
Dosage Forms & StrengthsÂ
Injectable IV solutions in concentrated formÂ
10mg/mL (Biorphen, Vazculep)Â
Need further dilutionÂ
Injectable IV solution as ready-to-useÂ
0.1 mg/mL (Biorphen)Â
Should not dilute furtherÂ
Indicated for Severe Hypotension or Shock as off-label
Age >2 years
5-20 mcg/kg intravenously one time; then after 0.1-0.5 mcg/kg/min intravenously. Should not exceed 3-5 mcg/kg/min intravenously
Age <2 years
Safety and efficacy not established
Refer to adult dosingÂ
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
decongestant: they may increase the hypertensive effect of Alpha 2-Agonists
decongestant: they may increase the hypertensive effect of Alpha 2-Agonists
decongestant: they may increase the hypertensive effect of Alpha 2-Agonists
decongestant: they may increase the hypertensive effect of Alpha 2-Agonists
decongestant: they may increase the hypertensive effect of Alpha 2-Agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
bunazosin (Not available in the United States)
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with beta/alpha-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
bunazosin (Not available in the United States)
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased therapeutic effect when combined with alpha1-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
Actions and Spectrum:Â
phenylephrine is a medication that acts as a selective alpha-1 adrenergic receptor agonist. It is used as a decongestant and vasoconstrictor to treat symptoms associated with nasal congestion, such as those caused by allergies or the common cold.Â
When administered, phenylephrine binds to the alpha-1 receptors in the smooth muscles of blood vessels, causing them to constrict. This results in increased blood pressure and reduced blood flow to the nasal mucosa, which can alleviate congestion.Â
phenylephrine also has some mild beta-1 adrenergic receptor activity, which can increase heart rate and contractility. However, the alpha-1 adrenergic receptor activity is more significant, and thus, the medication is primarily used for its vasoconstrictive effects.Â
Overall, the action of phenylephrine is to constrict blood vessels, increase blood pressure, and reduce nasal congestion. Its spectrum of activity is primarily limited to its effects on the alpha-1 adrenergic receptors in the smooth muscles of blood vessels.Â
Frequency not definedÂ
BurningÂ
HypertensionÂ
SneezingÂ
AnxietyÂ
ExtravasationÂ
NauseaÂ
HeadacheÂ
Gastric irritationÂ
Metabolic acidosisÂ
Rebound congestionÂ
Reflex bradycardiaÂ
Pulmonary edemaÂ
Decreased renal perfusionÂ
Reduced urine outputÂ
Black Box Warning:Â
phenylephrine has a black box warning for its use in patients with severe hypertension, particularly those with hypertensive crisis. The drug can cause a sudden and potentially dangerous increase in blood pressure in these patients, leading to complications such as stroke, heart attack, or kidney damage.Â
Patients with a prior history of cardiac diseases, including arrhythmias, angina, and myocardial infarction, should use phenylephrine cautiously, as the medication can increase heart rate and worsen these conditions.Â
Additionally, phenylephrine should not be used in patients taking monoamine oxidase inhibitors (MAOIs) or other drugs that can increase blood pressure, as this can lead to a hypertensive crisis.Â
Contraindication/Caution:Â
ContraindicationÂ
CautionÂ
Pregnancy consideration:Â Â
AU TGA pregnancy category: B2
US FDA pregnancy category: CÂ
Lactation:  Â
Excreted into human milk is Not known.Â
Pregnancy category:Â
Pharmacology:Â
phenylephrine is a sympathomimetic drug that acts as a selective alpha-1 adrenergic receptor agonist. When administered, it activates the alpha-1 adrenergic receptors in blood vessels and smooth muscles, leading to vasoconstriction and increased blood pressure.
This vasoconstrictive effect is particularly potent in the veins and capacitance vessels, leading to increased venous return and cardiac output. phenylephrine also acts on the alpha-1 adrenergic receptors in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.Â
Pharmacodynamics:Â
Mechanism of action: The medication has a mechanism of action that involves strong alpha effects, which leads to increased peripheral vascular resistance and blood pressure. As a result, it decreases cardiac output and renal perfusion.Â
Pharmacokinetics:Â
AbsorptionÂ
phenylephrine can be administered via different routes, such as oral, nasal, ophthalmic, and parenteral. When administered orally, the bioavailability is low (less than 38%) due to extensive first-pass metabolism in the liver. After nasal administration, phenylephrine is absorbed rapidly through the nasal mucosa, and onset of action is usually within 15 minutes. When administered as eye drops, it is absorbed through the cornea and reaches the systemic circulation through the conjunctival vessels.Â
DistributionÂ
phenylephrine has a moderate volume of distribution, indicating that it is distributed throughout the body. It is highly bound to plasma proteins, with a binding rate of approximately 95%. Phenylephrine can cross the placental barrier and is excreted in human breast milk.Â
MetabolismÂ
phenylephrine is metabolized in the liver and intestines by two main pathways: MAO (monoamine oxidase) and COMT (catechol-O-methyltransferase). The major metabolite of phenylephrine is conjugated phenylephrine, which is excreted in the urine. The half-life of phenylephrine is relatively short, approximately 2-3 hours.Â
Elimination and ExcretionÂ
phenylephrine and its metabolites are excreted primarily in the urine, with a small amount eliminated in the feces. The excretion of phenylephrine is dose-dependent and varies with the route of administration. After nasal administration, approximately 90% of the dose is generally eliminated in the urine within one day. After intravenous administration, 70-90% of the dose is eliminated in the urine within 24 hours.Â
Administration:Â
Intravenous administrationÂ
Depending on the treated condition, phenylephrine is typically administered as a nasal spray, eye drops, or injection. The drug should be generally used as directed by a healthcare provider.Â
Patient information leafletÂ
Generic Name: phenylephrineÂ
Pronounced: [ FEN-il-EFF-rin ]Â
Why do we use phenylephrine?Â
phenylephrine is a medication that has several therapeutic uses. Some of the common uses of phenylephrine include:Â